InvestorsHub Logo
Followers 87
Posts 6670
Boards Moderated 1
Alias Born 09/18/2009

Re: TankTheFrank post# 41114

Saturday, 12/02/2023 10:05:44 AM

Saturday, December 02, 2023 10:05:44 AM

Post# of 42838
Thanks for sharing this link, Tank. It was great to see this receive journal publication ahead of the ASH conference in regards to the PREACH-M study. Although I admit that I enjoyed Dr. Thomas' interviews far more on this subject. His excitement was contagious!

Newtg's article was in regards to lenzilumab representing the 4th arm of the C-SMART trial, which I think we pulled out of when the Australian government declared an end to the prioritization of covid trials.

I'm eagerly awaiting further updates on the aGvHD trial, after the first person was dosed and, as I recall, showed no continuing signs of CMML cancer.

for future reference:

https://ashpublications.org/blood/article/142/Supplement%201/1847/505640/Lenzilumab-in-Addition-to-Azacitidine-Improves

https://www.anzctr.org.au/TrialSearch.aspx#&&conditionCode=&dateOfRegistrationFrom=&interventionDescription=&interventionCodeOperator=OR&primarySponsorType=&gender=&distance=&postcode=&pageSize=20&ageGroup=&recruitmentCountryOperator=OR&recruitmentRegion=ðicsReview=&countryOfRecruitment=®istry=&searchTxt=Lenzilumab&studyType=&allocationToIntervention=&dateOfRegistrationTo=&recruitmentStatus=&interventionCode=&healthCondition=&healthyVolunteers=&page=1&conditionCategory=&fundingSource=&trialStartDateTo=&trialStartDateFrom=&phase=